Mylan Paying $465M to Settle Claims It Overcharged for EpiPens

Mylan Paying $465M to Settle Claims It Overcharged for EpiPens
AP Photo/Mark Zaleski, File

The government says EpiPen was mischaracterized as a generic drug.

Read Full Article »
Comment
Show commentsHide Comments

Related Articles